Fasteris

Executive Summary

Fasteris is a Swiss life science company specializing in Next-Generation Sequencing (NGS) and Sanger sequencing services for research and diagnostics. Founded in 2005 and headquartered in Plan-les-Ouates, Switzerland, the company provides a comprehensive range of genomic solutions including RNA-seq, DNA-seq, Whole Exome Sequencing (WES), and custom projects, supported by bioinformatics and extraction services. As a private entity, Fasteris has established itself as a reliable partner in the genomics value chain, serving academic, clinical, and industrial clients. The company's strong technical expertise and focus on quality have enabled it to maintain a steady market position in the competitive European genomics service market. With the increasing adoption of NGS in clinical diagnostics and precision medicine, Fasteris is well-positioned to benefit from growing demand for high-throughput sequencing and data analysis services. However, as a service provider with no disclosed pipeline of proprietary assets, its growth trajectory is closely tied to overall market trends and its ability to secure large-scale contracts. The company's private status limits visibility into financial performance and strategic initiatives, but its long operational history suggests resilience and a solid reputation within the Swiss and European biotech ecosystem.

Upcoming Catalysts (preview)

• Q2 2026Expansion into Clinical Diagnostics Certification (ISO 15189)70% success
• Q4 2026Strategic Partnership with Major Pharma for Clinical Trial Sequencing40% success
• Q3 2026Launch of Long-Read Sequencing Service50% success